Hengrui–Elevar HCC Combo Rejected Again

Company Hengrui Pharmaceuticals / Elevar Therapeutics Event Type Regulatory Rejection (FDA Complete Response Letter) Modality PD-1 Antibody + Oral VEGFR2 Inhibitor (Combination) Asset Camrelizumab + Rivoceranib Target PD-1 / VEGFR2 Disease Area Unresectable or Metastatic Hepatocellular Carcinoma Summary The FDA issued a third complete response…